Company Information
Industry 制造业
Company Introduction 宁波美诺华药业股份有限公司创立于2004年,总部设于浙江省宁波市,2017年4月7日在上交所主板上市,股票简称:美诺华,股票代码603538。 公司是一家专业从事特色原料药(包括中间体)和成品药研发、生产与销售的综合性国际医药科技制造型企业,是国内出口欧洲特色原料药品种最多的企业之一,连续多年荣膺“中国CDMO企业20强”。 公司产品覆盖心血管、中枢神经、胃肠消化道等治疗领域,核心品种缬沙坦、氯沙坦、氯吡格雷、培哚普利、瑞舒伐他汀钙、阿托伐他汀钙、普瑞巴林等多个产品已形成了全产业链商业化的研发、生产和销售体系。 凭借严谨的质量管理与EHS管理能力、扎实的工艺开发和高标准规模化的生产制造能力、以及精细高效的团队战斗力,公司已与国内外知名制药企业建立了长期深度稳定的合作关系。在CDMO细分行业领域、特色原料药细分行业内,已形成了较高的品牌国际知名度和竞争优势。 自上市以来,公司借力资本市场,“内涵式增长+外延式拓展”双轮驱动,在夯实强化特色原料药业务的同时,依托持续的研发创新和商务拓展,坚定深入“医药中间体、原料药、制剂”一体化战略,拓展延伸上游中间体和下游制剂业务,以进一步完善产业链布局、充分扩大一体化优势;同时,基于在特色原料药领域的竞争优势和客户网络资源,公司持续布局CDMO业务,加速打造CDMO一站式综合服务平台。通过持续完善多维度的战略布局,以CDMO业务和制剂一体化业务为核心,积极开展前沿的医学产品的开发和商业化,助力公司“二次创业”,致力于将美诺华打造成国内一流、国际知名、极具竞争力的国际医药科技制造型企业。
Main Business 特色原料药(包括中间体,下同)和制剂研发、生产与销售。
Legal Representative 姚成志
Top Executives
董事长:姚成志
董事:应高峰,姚芳
独立董事:贝洪俊,魏杰
Top 5 Shareholder
Shareholder name Nature Holding Date
宁波美诺华控股集团有限公司流通A股20.70%30/09/2024
姚成志流通A股5.52%30/09/2024
中国工商银行股份有限公司-融通健康产业灵活配置混合型证券投资基金流通A股2.63%30/09/2024
石建祥流通A股1.36%30/09/2024
杜广娣流通A股0.92%30/09/2024
Company Secretary 应高峰
Solicitors 上海市广发律师事务所
Auditors 立信会计师事务所(特殊普通合伙)
Tel No 0574-87916065
Fax No 0574-87918601
Website www.menovopharm.com/cn
Email nbmnh@menovopharm.com
Company Address
Register: 浙江省宁波市高新区扬帆路999弄1号1406室
Office: 浙江省宁波市高新区扬帆路999弄1号1406室
Listing Date 07/04/2017
Shares Capital
Shares Capital: 218,752,525
Total A Share: 218,752,525
Listed A Share: 212,259,636
Non-tradable A Share: 6,492,889
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.050
DPS(RMB)* ¥ 0.020
NBV Per Share(RMB)* ¥ 9.506
Market Capitalization(RMB) 2.887B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.